Difference between revisions of "Teniposide (Vumon)"

Latest revision as of 19:26, 23 June 2024

General information

Class/mechanism: Topoisomerase II inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.^[1]^[2]
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

1992-07-14: Initial approval for induction therapy in patients with refractory childhood acute lymphoblastic leukemia

History of changes in EMA indication

1976-04-05: EURD

Also known as

Code name: VM-26
Brand name: Vumon

References

[insert-1] 1.0 ^1.1 Teniposide (Vumon) package insert

[2] Teniposide (Vumon) package insert (locally hosted backup)

[3] Teniposide (Vumon) patient drug information (Chemocare)

[4] Teniposide (Vumon) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 1: / Line 1: @@
 ==General information==
-Class/mechanism: <ref name="insert">[http://packageinserts.bms.com/pi/pi_vumon.pdf Teniposide (Vumon) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/teniposide.pdf Teniposide (Vumon) package insert (locally hosted backup)]</ref>
+Class/mechanism: Topoisomerase II inhibitor.  Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks.  It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis.  It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http://packageinserts.bms.com/pi/pi_vumon.pdf Teniposide (Vumon) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/teniposide.pdf Teniposide (Vumon) package insert (locally hosted backup)]</ref>
-<br>Route: TBD
+<br>Route: IV
-<br>Extravasation: TBD
+<br>Extravasation: [[irritant]]
-For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.
+For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+==Diseases for which it is used==
+*[[B-cell acute lymphoblastic leukemia]]
+*[[Burkitt lymphoma]]
+*[[CNS lymphoma]]
+*[[HIV-associated lymphoma]]
+*[[Low-grade glioma]]
+*[[Small cell lung cancer]]
+==Diseases for which it was used==
+*[[Diffuse large B-cell lymphoma - historical|Diffuse large B-cell lymphoma]]
+*[[Follicular lymphoma_-_historical |Follicular lymphoma]]
 ==Patient drug information==
-*[http://chemocare.com/bio/teniposide.aspTeniposide (Vumon) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/teniposide.aspTeniposide (Vumon) patient drug information (Chemocare)]</ref>
+*[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]</ref>
 *[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]</ref>
+==History of changes in FDA indication==
+* 1992-07-14: Initial approval for induction therapy in patients with refractory childhood [[:Category:Acute lymphoblastic leukemias|acute lymphoblastic leukemia]]
+==History of changes in EMA indication==
+*1976-04-05: EURD
+==Also known as==
+*'''Code name:''' VM-26
+*'''Brand name:''' Vumon
 ==References==
 <references/>
+[[Category:Drugs]]
+[[Category:Intravenous medications]]
+[[Category:Irritant]]
+[[Category:Topoisomerase II inhibitors]]
+[[Category:B-cell acute lymphoblastic leukemia medications]]
+[[Category:Burkitt lymphoma medications]]
+[[Category:CNS lymphoma medications]]
+[[Category:HIV-associated lymphoma medications]]
+[[Category:Low-grade glioma medications]]
+[[Category:Small cell lung cancer medications]]
+[[Category:Diffuse large B-cell lymphoma medications (historic)]]
+[[Category:Follicular lymphoma medications (historic)]]
+[[Category:FDA approved in 1992]]
+[[Category:EMA approved in 1976]]